News & Events

Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC

Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC

Roche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLC

Roche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLC

Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial

Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial

Roche Reports Positive Clinical Trial Results for Divarasib in KRAS G12C-Mutated Lung Cancer

Roche Reports Positive Clinical Trial Results for Divarasib in KRAS G12C-Mutated Lung Cancer

Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C Non-Small Cell Lung Cancer

Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C Non-Small Cell Lung Cancer

Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer

Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer

Roche Divarasib Beats Approved KRAS Inhibitors in Phase III

Roche Divarasib Beats Approved KRAS Inhibitors in Phase III

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche s Divarasib Shows Promising Results in Advancing Lung Cancer Treatment for KRAS G12C Patients

Roche s Divarasib Shows Promising Results in Advancing Lung Cancer Treatment for KRAS G12C Patients

Roche Reports P-III (Krascendo 1) Trial Results on Divarasib for KRAS G12C-Mutant NSCLC

Roche Reports P-III (Krascendo 1) Trial Results on Divarasib for KRAS G12C-Mutant NSCLC